Cargando…

Comparison of Different First-Line Systemic Therapies in Advanced Biliary Tract Cancer Based on Updated Random Controlled Trials: A Systematic Review and Network Meta-Analysis

METHODS: We searched PubMed, Web of Science, and Cochrane Library for abstracts and full-text articles published from database inception through May 2022. All the random controlled trials (RCTs) were assessed and collected as eligible studies. The primary outcome was overall survival (OS). The secon...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Long, Wang, Ying, Xu, Haoqian, Yi, Fengming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9481325/ https://www.ncbi.nlm.nih.gov/pubmed/36119936 http://dx.doi.org/10.1155/2022/1720696

Ejemplares similares

The Efficacy and Safety of First-line Chemotherapies for Advanced Biliary Tract Cancer: A Network Meta-analysis
por: Zheng, Wei, et al.
Publicado: (2019)

Lenvatinib Beyond First-Line Therapy in Patients With Advanced Biliary Tract Carcinoma
por: Wang, Yunchao, et al.
Publicado: (2022)

Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis
por: Jiang, Yanfeng, et al.
Publicado: (2021)

Updates in Biliary Tract Cancers
por: Li, Daneng, et al.
Publicado: (2022)

Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection
por: Ye, Yanyan, et al.
Publicado: (2023)

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Imaging of malignancies of the biliary tract- an update
por: Hennedige, Tiffany Priyanthi, et al.
Publicado: (2014)

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer
por: Zeng, Tian-mei, et al.
Publicado: (2023)

Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials
por: Chen, Lawrence, et al.
Publicado: (2016)

The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
por: Sun, Xin-Fang, et al.
Publicado: (2017)

The Efficacy of Different Chemotherapy Regimens for Advanced Biliary Tract Cancer: A Systematic Review and Network Meta-Analysis
por: Li, Yan, et al.
Publicado: (2019)

A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
por: Ulusakarya, Ayhan, et al.
Publicado: (2020)

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India
por: Bhargava, Prabhat G., et al.
Publicado: (2020)

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
por: Wang, Longrong, et al.
Publicado: (2023)

Efficacy and toxicities of adding molecular targeted agents to first-line chemotherapy in the treatment of advanced biliary tract cancer: a systematic review and meta-analysis
por: Zhao, Sheng, et al.
Publicado: (2016)

Essential updates to the surgical treatment of biliary tract cancer
por: Matsukuma, Satoshi, et al.
Publicado: (2019)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
por: Faloppi, Luca, et al.
Publicado: (2016)

Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy
por: Suzuki, Yuko, et al.
Publicado: (2018)

Efficacy and Safety of First-Line Targeted Treatment and Immunotherapy for Patients with Biliary Tract Cancer: A Systematic Review and Meta-Analysis
por: Yan, Xin, et al.
Publicado: (2022)

Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
por: Ye, Zhuo-miao, et al.
Publicado: (2023)

Combination Therapies for Advanced Biliary Tract Cancer
por: Zeng, Weifeng, et al.
Publicado: (2023)

Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)
por: Javle, M.M., et al.
Publicado: (2021)

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
por: Hyung, Jaewon, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
por: Chen, Ruijia, et al.
Publicado: (2022)

A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer
por: Takahara, Naminatsu, et al.
Publicado: (2022)

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial
por: Zhao, Qiuling, et al.
Publicado: (2023)

Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy
por: Moriwaki, Toshikazu, et al.
Publicado: (2016)

Update on first-line treatment of advanced ovarian carcinoma
por: Kemp, Z, et al.
Publicado: (2013)

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2023)

Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
por: Moik, Florian, et al.
Publicado: (2019)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019)

Systemic treatment options for advanced biliary tract carcinoma
por: Xie, Changqing, et al.
Publicado: (2020)

Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
por: Kang, Sandra, et al.
Publicado: (2022)

Clinical Advances in the Diagnosis and Treatment of Biliary Tract Diseases
por: Matsubara, Saburo
Publicado: (2023)

Main causes of death in advanced biliary tract cancer
por: Kimura‐Seto, Kana, et al.
Publicado: (2023)

Durvalumab: A Review in Advanced Biliary Tract Cancer
por: Fung, Simon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5nv1b8mfosjm7its9teee3u0em